Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GNPX |
---|---|---|
09:32 ET | 302 | 2.48 |
09:41 ET | 300 | 2.5284 |
09:45 ET | 217 | 2.4514 |
09:56 ET | 100 | 2.43 |
10:01 ET | 1000 | 2.4101 |
10:06 ET | 1000 | 2.4205 |
10:08 ET | 1510 | 2.4201 |
10:15 ET | 100 | 2.55 |
10:37 ET | 100 | 2.535 |
10:55 ET | 190 | 2.54 |
11:02 ET | 3700 | 2.61 |
11:09 ET | 1000 | 2.6 |
11:11 ET | 100 | 2.6349 |
11:18 ET | 900 | 2.54 |
11:20 ET | 500 | 2.5152 |
11:38 ET | 1552 | 2.54 |
11:44 ET | 1241 | 2.54 |
11:45 ET | 2362 | 2.5013 |
12:02 ET | 400 | 2.5108 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Genprex Inc | 5.3M | -0.1x | --- |
Lixte Biotechnology Holdings Inc | 5.2M | -1.0x | --- |
Synaptogenix Inc | 5.1M | -0.1x | --- |
Portage Biotech Inc | 5.1M | 0.0x | --- |
Transcode Therapeutics Inc | 4.9M | 0.0x | --- |
CeCors Inc | 4.8M | 0.0x | --- |
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid nanoparticles. The Company’s lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Using a different gene therapy delivery system, the Company is also developing its preclinical diabetes candidate GPX-002 using the same construct for both Type 1 diabetes and Type 2 diabetes. It conducts preclinical research to explore how REQORSA may be administered in other solid tumors.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.3M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 2.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.59 |
EPS | $-22.93 |
Book Value | $4.99 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.